Authors: Chen L, Chubak J, Boudreau DM, Barlow WE, Weiss NS, Li CI
Title: Use of antihypertensive medications and risk of adverse breast cancer outcomes in a SEER-Medicare population.
Journal: Cancer Epidemiol Biomarkers Prev :-
Date: 2017 Aug 14
Abstract: BACKGROUND: It is unclear if use of common antihypertensive medications influences the risk of adverse breast cancer outcomes. METHODS: Using the linked Surveillance, Epidemiology and End-Results (SEER)-Medicare database, we identified 14,766 women between ages 66 and 80 years diagnosed with incident stage I/II breast cancer between 2007-2011. Medicare Part D data were obtained to characterize women's post-cancer use of various antihypertensive medications. Outcomes included a second breast cancer event (SBCE, a composite outcome defined as the first of a recurrence or a second contralateral primary breast cancer), breast cancer recurrence, and breast-cancer specific mortality. Time-varying Cox proportional hazard models were used to estimate hazard ratios (HRs) and their associated 95% confidence intervals (CIs). RESULTS: There were 791 SBCEs, 627 breast cancer recurrences, and 237 breast cancer deaths identified over a median follow-up of 3 years. Use of diuretics (n=8,517) after breast cancer diagnosis was associated with 29% (95% CI: 1.10-1.51), 36% (95% CI: 1.14-1.63) and 51% (95% CI: 1.11-2.04) higher risks of a SBCE, recurrence, and breast cancer death, respectively. Compared to nonusers, β-blockers users (n=7,145) had a 41% (95% CI: 1.07-1.84) higher risk of breast cancer death. Use of angiotensin II receptor blockers, calcium channel blockers and angiotensin-converting enzyme inhibitors were not associated with risks of breast cancer outcomes. CONCLUSIONS: Use of diuretics and β-blockers may be associated with increased risk of breast cancer outcomes among older women. IMPACT: Most antihypertensive medications are safe with respect to breast cancer outcomes, but more research is needed for diuretics and β-blockers.
Last Updated: 02 Mar 2015